Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 10/20 | 0.69 |
| ▸ | IKZF2 | Q9UKS7 | 9/20 | 0.61 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.58 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.58 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15128601 | 1.00 | CRBN (0.69) | CRBNIKZF2GSPT1DDB1IKZF3 | |
| SCHEMBL23657089 | 0.91 | CRBN (0.66) | CRBNIKZF2GSPT1DDB1IKZF3 | |
| SCHEMBL24501690 | 0.91 | CRBN (0.69) | CRBNIKZF2GSPT1 | |
| SCHEMBL19503721 | 0.91 | CRBN (0.69) | CRBNIKZF2GSPT1 | |
| SCHEMBL25228921 | 0.89 | CRBN (0.70) | CRBNIKZF2GSPT1DDB1IKZF3 | |
| SCHEMBL26270738 | 0.89 | CRBN (0.70) | CRBNIKZF2GSPT1DDB1IKZF3 | |
| SCHEMBL24991548 | 0.88 | CRBN (0.69) | CRBNIKZF2GSPT1DDB1IKZF3 | |
| SCHEMBL25234569 | 0.88 | CRBN (0.69) | CRBNIKZF2GSPT1DDB1IKZF3 | |
| SCHEMBL68272 | 0.88 | CRBN (0.72) | CRBNIKZF2GSPT1DDB1IKZF3 | |
| SCHEMBL24600532 | 0.88 | CRBN (0.69) | CRBNIKZF2GSPT1DDB1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023081759-A1 | BIFUNCTIONAL PI3K-ALPHA INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |